Man performing a seated cable row with another man beside him.

Prostate Cancer Exercise: What Different Trials Test

Compare prostate cancer exercise trials on heart-risk scores, fatigue, fitness and tumor biomarkers, including what each study can and cannot establish.

Image context: The gym scene is an illustration, not a photograph of identified trial participants or a demonstration of a study protocol.

Prostate cancer exercise trials study fatigue, fitness, cardiovascular risk or tumor biology. One measured outcome does not establish every benefit.

That distinction matters when a headline says an exercise trial was successful. The first question is what the investigators actually tested, in whom, and against which comparison.

This guide compares three research programs, including two different studies called POWER. It explains how to read their findings and trial invitations without turning a research schedule into a personal exercise prescription.

Three prostate cancer exercise questions

The studies below concern different treatment settings and different outcomes. Their names alone cannot tell you which findings apply to the question you are asking.

Study identifier Population and comparison Question being tested
Dana-Farber POWER
NCT05327465
Black men receiving androgen deprivation therapy; planned randomization to exercise or a waitlist. Whether a 16-week program changes estimated cardiovascular risk and other outcomes.
Huntsman POWER
NCT03421782
Advanced prostate cancer; both listed study arms receive exercise, with internet-based cognitive behavioral therapy added in one arm. Fatigue, fitness and related patient-reported outcomes.
MSK pre-surgery study
NCT03813615
Inactive men with untreated localized cancer awaiting surgery; nonrandomized exercise dose finding. Feasibility and exploratory tumor-biomarker activity.

The identifiers are useful when searching for updates or asking a study team about a report. Matching the acronym POWER is insufficient because it can lead to a different population, design and outcome.

Dana-Farber POWER is a cardiovascular-risk protocol

The published Dana-Farber POWER protocol plans 62 participants, allocated equally to a culturally tailored, remotely supervised cardiovascular and strength program or a waitlist control. Its primary endpoint is the Framingham Risk Score, with other fitness, function and patient-reported measures.

A protocol describes planned methods, not completed results. Even a favorable change in estimated cardiovascular risk would need to be distinguished from demonstrating fewer heart attacks or longer survival.

When reading an update, look for whether it reports the planned comparison and its actual participants. The planned enrollment number should not be silently relabeled as the number who completed treatment or contributed usable follow-up data.

Similarly, a planned secondary outcome is not a result just because it appears in a registry. A useful update identifies the measurement, the time point, the comparison and the uncertainty around the estimate.

Huntsman POWER asks a different fatigue question

The NCI description of Huntsman POWER outlines a 12-week program and two randomized arms. Both include exercise; one also includes internet-based cognitive behavioral therapy, so that design is different from exercise versus no exercise.

A 2025 meeting abstract reports 119 enrolled participants, 92% with metastatic disease. Fatigue was evaluable in 72, while 76 completed both aerobic-fitness assessments.

It reports improved fatigue and a mean fitness increase of 3.1 mL/kg/min, with a 95% confidence interval of 2.1 to 4.0, from baseline to 12 weeks. These reported before-and-after findings are not a randomized exercise-versus-no-exercise effect.

Withdrawal, loss to follow-up and incomplete data are reported, including disruption during COVID. The before-and-after figures do not quantify the added effect of cognitive behavioral therapy.

Enrolled and assessed are different denominators; the reported measurements do not describe every participant.

Reported improvement and unanswered comparisons can coexist.

The MSK study

The 2024 MSK phase 1a study enrolled 53 inactive men with untreated localized prostate cancer awaiting surgery. Its nonrandomized design tested remotely monitored treadmill-walking doses and selected 225 minutes weekly for further phase 2 research.

The reported 95% confidence intervals for changes in both Ki67, a tumor cell-proliferation marker, and PSA included zero at every dose. The authors describe promising activity, but these exploratory estimates do not establish a reliable biomarker reduction or a survival benefit.

Selecting a dose for further research does not prove improved cancer outcomes or set a personal treatment threshold.

Suitability depends on treatment context, assessment and monitoring; a selected trial population cannot establish a workload for everyone.

Read the outcome and the comparison together

A headline can accurately name an improvement while leaving the most useful detail unstated. Pair each result with the question below before deciding what it means.

If a report mentions… Look for… Avoid assuming…
An estimated risk score The score, time point and control-group difference. That clinical events were actually prevented.
Less fatigue or greater fitness Who supplied follow-up data and whether the result is within one group or between groups. That all enrolled participants improved or that the comparison isolated exercise.
A tumor biomarker The estimate, confidence interval and whether clinical cancer outcomes were measured. That a laboratory signal proves delayed progression or longer life.
A feasible exercise amount The selected population, support and purpose of the next trial. That it is a universal minimum, maximum or treatment prescription.

This table is a reading aid, not a scoring system for deciding whether to join a trial or change treatment. A study can be informative about feasibility while leaving effectiveness uncertain.

For example, imagine a short report that says “fitness improved after the program.” Without knowing the comparator, you cannot tell whether that sentence describes change over time, an advantage over usual care, or an advantage over another active program.

The missing detail is worth finding rather than filling in from the headline. If the available abstract does not provide it, write “not reported here” in your notes.

A home-based trial can still involve travel

Dana-Farber’s official POWER listing was labeled enrolling when reviewed for this article. Its NCI listing describes virtually supervised exercise but also requires travel for necessary data collection.

A recruitment label does not establish that a particular person qualifies, that a place remains available, or that every visit can happen remotely. Confirm the current study identifier and practical arrangements with the listed study team.

Before committing time to a screening visit, ask which parts occur at home, which require attendance, and what technology or assistance is supplied. Separate ordinary treatment appointments from research visits and ask how the study fits the existing care plan.

These are access questions rather than an attempt to self-apply the eligibility criteria. A registry’s screening rules are study procedures, not a home clearance checklist.

Make a one-page study card

Keep one card per study so that a shared acronym or a dramatic headline does not mix unrelated evidence. Copy the fields below into a notebook or document.

  • Identity: Full title, institution and NCT identifier.
  • People: Cancer setting, treatment context and the actual number assessed for the outcome of interest.
  • Comparison: Exercise versus what, including what both groups received.
  • Outcome: The exact symptom, test, risk estimate or clinical event, plus the assessment time.
  • Report type: Recruitment listing, protocol, conference abstract or completed results publication.
  • Open question: One detail the report does not answer and the source or study team that could clarify it.

A useful final line is: “This report answers ___, but it does not establish ___.” Filling that sentence with a measured outcome is more informative than labeling the whole study positive or negative.

Keep the original source link with the card. When a later report appears, compare its identifier, participants and outcome definitions before treating it as an update to the same result.

Use trial evidence alongside clinical exercise guidance

Research interpretation and selecting an appropriate exercise plan are related tasks with different requirements. Our separate prostate cancer exercise guidelines article explains the guidance and care-planning context.

Bring the study card to a conversation with the oncology team if a trial or headline raises a question about your care. It helps identify the actual claim without presenting a research dose, fatigue score or eligibility rule as personal medical advice.

References

Kang DW et al. Dana-Farber POWER study protocol. Contemporary Clinical Trials. 2025. DOI: 10.1016/j.cct.2025.107973.

National Cancer Institute. Huntsman POWER trial listing. NCT03421782. Accessed October 28, 2026.

Huntsman POWER meeting abstract. Journal of Clinical Oncology. 2025;43(5_suppl):120. Conference abstract. DOI: 10.1200/JCO.2025.43.5_suppl.120.

Jones LW et al. MSK pre-surgery exercise study. JAMA Oncology. 2024;10(9):1187 to 1194. DOI: 10.1001/jamaoncol.2024.2156. Corrected abstract indexed by PubMed.

Dana-Farber Cancer Institute. Dana-Farber POWER trial listing. NCT05327465; protocol 21-741. Also listed by the National Cancer Institute. Accessed October 28, 2026.

Medical disclaimer: This article provides general exercise and health information, not medical advice or a cancer-treatment plan. Discuss exercise, symptoms and trial participation with your oncology team and an appropriately qualified exercise professional.

Share your love
Chris Pruitt, certified personal trainer and WorkoutHealthy founder
Chris Pruitt

Chris Pruitt is a certified ASFA personal trainer and the founder of WorkoutHealthy, a fitness equipment retailer serving customers since 2007. He has more than 16 years in the fitness business, and he writes and fact checks everything published on Insider.

The Insider Five

Five stories worth your time, every Friday. One email a week, no pitches.